Posimir is a drug owned by Innocoll Pharmaceuticals Ltd. It is protected by 6 US drug patents filed from 2021 to 2023. Out of these, 2 drug patents are active and 4 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 12, 2041. Details of Posimir's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11771624 | Sustained release drug delivery systems with reduced impurities and related methods |
Jan, 2041
(14 years from now) | Active |
| US11400019 | Sustained release drug delivery systems with reduced impurities and related methods |
Jan, 2041
(14 years from now) | Active |
| US8753665 | Controlled delivery system |
Sep, 2025
(1 year, 1 month ago) |
Expired
|
| US8846072 | Controlled delivery system |
Sep, 2025
(1 year, 1 month ago) |
Expired
|
| US8153661 | Controlled delivery system |
Sep, 2025
(1 year, 1 month ago) |
Expired
|
| US8153149 | Controlled delivery system |
Sep, 2025
(1 year, 1 month ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Posimir's patents.
Latest Legal Activities on Posimir's Patents
Given below is the list of recent legal activities going on the following patents of Posimir.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Jan, 2026 | US11400019 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Nov, 2025 | US8753665 |
| Patent eCofC Notification | 20 May, 2025 | US8153661 |
| Recordation of Patent eCertificate of Correction | 20 May, 2025 | US8153661 |
| Mail Patent eCofC Notification | 20 May, 2025 | US8153661 |
| Post Issue Communication - Certificate of Correction | 29 Apr, 2025 | US8153661 |
| Mail Certificate of Correction Memo | 14 Mar, 2025 | US8153661 |
| Certificate of Correction Memo | 12 Mar, 2025 | US8153661 |
| Post Issue Communication - Certificate of Correction | 13 Oct, 2023 | US11400019 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 Oct, 2023 | US8153149 |
FDA has granted several exclusivities to Posimir. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Posimir, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Posimir.
Exclusivity Information
Posimir holds 1 exclusivities. All of its exclusivities have expired in 2024. Details of Posimir's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 01, 2024 |
US patents provide insights into the exclusivity only within the United States, but
Posimir is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Posimir's family patents as well as insights into
ongoing legal events
on those patents.
Posimir's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Posimir:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Generic Launch
Generic Release Date:
Posimir's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 12, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Posimir Generic API suppliers:
Bupivacaine is the generic name for the brand Posimir. 1 company has already filed for the generic of Posimir. Check out the entire list of companies who have already received approval for Posimir's generic
Alternative Brands for Posimir
Posimir which is used for providing sustained local anesthesia for at least 24 hours after surgery., has several other brand drugs using the same active ingredient (Bupivacaine). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Heron Theraps Inc |
| |
| Innocoll Pharms |
| |
| Pacira Pharms Inc |
| |
| Purdue Pharma Lp |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Bupivacaine, Posimir's active ingredient. Check the complete list of approved generic manufacturers for Posimir
About Posimir
Posimir is a drug owned by Innocoll Pharmaceuticals Ltd. It is used for providing sustained local anesthesia for at least 24 hours after surgery. Posimir uses Bupivacaine as an active ingredient. Posimir was launched by Innocoll in 2021.
Approval Date:
Posimir was approved by FDA for market use on 01 February, 2021.
Active Ingredient:
Posimir uses Bupivacaine as the active ingredient. Check out other Drugs and Companies using Bupivacaine ingredient
Treatment:
Posimir is used for providing sustained local anesthesia for at least 24 hours after surgery.
Dosage:
Posimir is available in solution form for infiltration use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 660MG/5ML (132MG/ML) | SOLUTION | Discontinued | INFILTRATION |